2020 Analytics of the Microbiome Landscape: Publication Analytics (2011-2019), Grants Analytics (2011-2019), Clinical Trial Analytics (2015-2020), Startup Activity (2015-2020)

DUBLIN, Dec. 15, 2020 /PRNewswire/ -- The "2020 Analytics of the Microbiome Landscape" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The report gives insights into the transformational microbiome landscape. It is a rigorous assessment of the industry trends supported by detailed segmentation across publications, grants, clinical trials, and startup funding activity.

The dataset behind the report is based on real world evidence that will drive actionable business insights. Follow trends over the years captured across publications, grants, clinical trials, and startup funding activity to power data driven marketing campaigns to fund raising to investor pitches, and business/corporate development activities. Tap into premium data sources that leverage NLP and relational search paradigm to uncover relevant data points, all in one package.

The report is unique in focusing on the real-world evidence of activity and uptake within these four pillars:

    --  Publication of scientific papers focused on microbiome research has been
        surging. A Chinese funding agency is the leading body that has been
        supporting a lot of published research, this is especially notable given
        the current contentious climate with China.
    --  Microbiome research grants continue to increase. Infectious disease and
        cancer researchers are the top award recipients. The US and EU have the
        most funding.
    --  COVID-19 has not dented the number of ongoing clinical trials focused on
        the microbiome. It has an unprecedented influence in the field of
        Oncology trials. Infectious disease is the main one in the microbiome
        pipeline is focused on a wide variety of indications.
    --  Exponential growth in investment has been seen in microbiome focused
        companies. 2020 has been a landmark time for the field of microbiome
        with investors betting big in companies in agriculture, food, and
        infectious disease.

Key Topics Covered:

1. Introduction: Report Scope and Methodology

2. Microbiome Based Publication Analytics (2011-2019)

    --  Volume trend
    --  Distribution by region and countries
    --  Distribution by diseases
    --  Top 50 Researchers, Trends for Top 5 Researchers
    --  Top 50 Funding agencies with the most Publications

3. Microbiome Based Grants Analytics (2011-2019)

    --  Funding trend
    --  Distribution by region and countries
    --  Distribution by diseases
    --  Top 50 Funding agencies with the most Grants
    --  Top 50 Institutions with the most Funding
    --  Top 50 Researchers with the most Funding

4. Microbiome Based Clinical Trial Analytics (2015-2020)

    --  Ongoing trials trend
    --  Distribution by region and countries
    --  Distribution by phase and sponsor type
    --  Top 10 sponsors and top 10 companies with most ongoing microbiome trials
    --  Distributions by top 10 therapy areas and indications
    --  Distributions by endpoint classification, molecule type, and
        interventions

5. Microbiome Based startup Activity (2015-2020)

    --  Investment trend
    --  Distribution by countries
    --  Distribution by funder type and funding round
    --  Microbiome investing by industry and disease area
    --  Top 5 Investors
    --  Top 3 companies from 2015-2020 that have raised the most capital

Companies Mentioned

    --  4D Pharma Plc
    --  Adare Pharmaceuticals
    --  Afineur
    --  Albert Einstein College of Medicine (AECOM)
    --  Arranta Bio
    --  AstraZeneca Plc
    --  Baylor College of Medicine
    --  Biotechnology and Biological Sciences Research Council (BBSRC)
    --  Canadian Institutes of Health Research (CIHR)
    --  Chinese Academy of Sciences (CAS)
    --  Computomics
    --  Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
    --  CosmosID
    --  Directorate for Biological Sciences (NSF BIO)
    --  Enterome Bioscience SA
    --  European Commission (EC)
    --  European Research Council (ERC)
    --  Evolve BioSystems
    --  Evolve Biosystems Inc
    --  Finch Therapeutics
    --  Flanders Institute for Biotechnology (VIB)
    --  German Research Foundation (DFG)
    --  Harvard University
    --  Icahn School of Medicine at Mount Sinai (MSSM)
    --  Imperial College London
    --  Indigo Ag
    --  Intralytix
    --  Japan Society for the Promotion of Science (JSPS)
    --  Joyn Bio
    --  Kaleido Biosciences Inc
    --  Karius
    --  Karolinska Institute (KI)
    --  King's College London (KCL)
    --  Lodo Therapeutics
    --  Massachusetts General Hospital (MGH)
    --  Medical Research Council (MRC)
    --  Microbiome Diagnostics Partners
    --  Ministry of Economy, Industry and Competitiveness (MINECO)
    --  Ministry of Science and Technology of the People's Republic of China
        (MOST)
    --  National Agency for Research (ANR )
    --  National Cancer Institute (NCI)
    --  National Center for Advancing Translational Sciences (NCATS)
    --  National Council for Scientific and Technological Development (CNPq)
    --  National Heart Lung and Blood Institute (NHLBI)
    --  National Human Genome Research Institute (NHGRI)
    --  National Institute for Health Research (NIHR)
    --  National Institute of Allergy and Infectious Diseases (NIAID)
    --  National Institute of Child Health and Human Development (NICHD)
    --  National Institute of Dental and Craniofacial Research (NIDCR)
    --  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    --  National Institute of Environmental Health Sciences (NIEHS)
    --  National Institute of Food and Agriculture (NIFA)
    --  National Institute of General Medical Sciences (NIGMS)
    --  National Natural Science Foundation of China (NSFC)
    --  National Research Foundation of Korea (NRF)
    --  Natural Sciences and Engineering Research Council (NSERC)
    --  Nubiyota LLC
    --  Nuritas
    --  Office of the Director (OD)
    --  Perfect Day
    --  Queen's University Belfast (QUB)
    --  Seres Therapeutics Inc
    --  Summit Therapeutics Plc
    --  Swiss National Science Foundation (SNF)
    --  Synlogic Inc
    --  TargEDys
    --  United States Department of Agriculture (USDA)
    --  University of Alabama at Birmingham (UAB)
    --  University of California, Los Angeles (UCLA)
    --  University of California, San Diego (UCSD)
    --  University of Cambridge
    --  University of Chicago (UC)
    --  University of Copenhagen (UCPH)
    --  University of Maryland, Baltimore (UMAB)
    --  University of Michigan (UM)
    --  University of North Carolina at Chapel Hill (UNC)
    --  University of Pittsburgh
    --  Vedanta Biosciences Inc
    --  Viome
    --  Vyome Therapeutics
    --  Washington University in St. Louis (WUSTL)
    --  Wellcome Trust (WT)

For more information about this report visit https://www.researchandmarkets.com/r/2qqnd5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2020-analytics-of-the-microbiome-landscape-publication-analytics-2011-2019-grants-analytics-2011-2019-clinical-trial-analytics-2015-2020-startup-activity-2015-2020-301192862.html

SOURCE Research and Markets